Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27625510 | 0.99 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Hydrochloric Acid SCHEMBL10584588 | 0.99 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL2176024 | 0.95 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL607047 | 0.95 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Pyrophosphoric Acid SCHEMBL2800166 | 0.91 | P2RY6 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL425422 | 0.90 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Triphosphate SCHEMBL28074755 | 0.89 | P2RY6 (0.49) | P2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL28176484 | 0.89 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL29824657 | 0.87 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL29834191 | 0.87 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4102 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122055151-A | Low dose regimen of fluorouridine and method of treating cancer with fluorouridine | JND治疗股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122028920-A | Method for treating hematological cancer | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | claimed |
| EP-3573623-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF FACTOR XII GENE EXPRESSION | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-04 | — | — | EP | claimed |
| CN-121586579-A | Methods for treating IGF-1R-related cancers with insulin-like growth factor 1 receptor ligands conjugated to cytotoxic agents | 利鲁姆治疗公司 | 2026-02-27 | — | — | CN | claimed |
| US-20250268993-A1 | ALKALINE PHOSPHATE-BASED ONCOLOGY TREATMENTS | THERIVA BIOLOGICS, INC. | 2025-08-28 | — | — | US | claimed |
| CN-120131971-A | Pyrimidine analogue and autophagy inhibitor co-carried liposome and preparation thereof | 浙江大学 | 2025-06-13 | — | — | CN | claimed |
| US-12318434-B2 | Alkaline phosphate-based oncology treatments | THERIVA BIOLOGICS, INC. (US) | 2025-06-03 | — | — | US | claimed |
| CN-120077031-A | Prodrug kit for multitube concurrent chemotherapy | 亚历克斯·祖内克 | 2025-05-30 | — | — | CN | claimed |
| CN-120076809-A | Combination therapy of CDK7 inhibitors with other anti-cancer therapies | 奎利恩特有限公司 | 2025-05-30 | — | — | CN | claimed |
| JP-2584947-B2 | — | — | 1997-02-26 | — | — | JP | claimed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | claimed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | claimed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | claimed |
| EP-0504279-A4 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | — | 1993-02-17 | — | — | EP | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| EP-0504279-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES. | CHEMGEN CORP (US) | 1992-09-23 | — | — | EP | claimed |
| WO-1991009130-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORPORATION (US) | 1991-06-27 | — | — | WO | claimed |